Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Myles, T. McKeever, Z. Hoare, C. Smith, R. Hubbard (Nottingham, United Kingdom). The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants. Eur Respir J 2008; 32: Suppl. 52, 611

Member's Comments

No comment yet.

Related content which might interest you: Microbial evaluation of proton-pump inhibitors and the risk of pneumonia Source: Eur Respir J 2011; 38: 1165-1172 Year: 2011 The risk of community-acquired pneumonia in children using gastric acid suppressants Source: Eur Respir J, 58 (4) 2003229; 10.1183/13993003.03229-2020 Year: 2021 Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia Source: Eur Respir J 2008; 31: 611-617 Year: 2008 Inhaled drugs as risk factors for community-acquired pneumonia Source: Eur Respir J 2010; 36: 1080-1087 Year: 2010 Correlation between the use of statins and ACE inhibitors with the length of hospitalization for COPD exacerbations Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Inhaled drugs as risk factors for community-acquired pneumonia Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Combination versus monotherapy for nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 50-55 Year: 2007 Influence of prior nonsteroidal anti-inflammatory steroidal drugs (NSAID) on the presentation and evolution of hospitalized community-acquired pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018 ACE inhibitors prevent aspiration pneumonia in Asian, but not Caucasian, elderly patients with stroke Source: Eur Respir J 2007; 29: 218-219 Year: 2007 Are statins beneficial for viral pneumonia? Source: Eur Respir J 2013; 41: 1010-1011 Year: 2013 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Associations of aspirin, statins and metformin with lung cancer risk and related mortality Source: Breathe, 17 (2) 200325; 10.1183/20734735.0325-2020 Year: 2021 Statin therapy and reduced risk of pneumonia in elderly patients with diabetes Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006